Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 193 alone and with docetaxel in advanced MTAP-null solid tumors
2023-504363-17-00Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label trial of anvumetostat in Nonhematologic neoplasms (2 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities (DLTs) in Parts 1 and 2, Treatment-emergent adverse events in Parts 1 and 2 and 3 more. Started Aug 2024; status: completed.
02
Drugs
anvumetostat
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-504363-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504363-17-00.